По вашему запросу найдено документов: 72

Страница 6 из 8

SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) FOR STROKE RECOVERY
LEGG, L.A., TILNEY, R., HSIEH, C.F., WU, S., LUNDSTRÖM, E., RUDBERG, A.S., KUTLUBAEV, M.A., DENNIS, M., MEAD, G.E., SOLEIMANI, B., BARUGH, A., HACKETT, M.L., HANKEY, G.J (2019)
excluded drugs with mixed pharmacological effects. The comparator was usual care or placebo. To be included
Innovative antimicrobial substances based on uracil S-derivatives
Meshcheryakova, S., Shumadalova, A., Beylerli, O., Gareev, I., Zhao, S., Wu, J. (2022)
THE BURDEN OF DISEASE IN RUSSIA FROM 1980 TO 2016: A SYSTEMATIC ANALYSIS FOR THE GLOBAL BURDEN OF DISEASE STUDY 2016
STARODUBOV, V.I., MARCZAK, L.B., VARAVIKOVA, E., BIKBOV, B., ERMAKOV, S.P., GALL, J., GLENN, S.D., GRISWOLD, M., IDRISOV, B., KRAVCHENKO, M., LIOZNOV, D., LOYOLA, E., RAKOVAC, I., VLADIMIROV, S.K., VLASSOV, V., MURRAY, C.J.L., NAGHAVI, M (2018)
to behavioural risk factors, including alcohol use, drug use, and smoking. Interpretation Trends in mortality
EnDuo, a novel derivative of Endostar, inhibits the migration of colon cancer cells, suppresses matrix metalloproteinase-2/9 expression and impedes AKT/ERK activation
Idiiatullina, E., Al-Azab, M., Walana, W., V.N. Pavlov, Liu, B. (2021)
-colon cancers drugs are urgently needed. In this study, we investigated the anti-metastatic property EnDuo, a
MOLECULAR DOCKING AND PRECLINICAL STUDY OF FIVE-MEMBERED S,S-PALLADAHETEROCYCLE AS HEPATOPROTECTIVE AGENT
AKHMADIEV, N.S., AKHMETOVA, V.R., IBRAGIMOV, A.G., GALIMOVA, A.M., GALIMOVA, R.A., AGLETDINOV, E.F., KATAEV, V.A., KHAIRULLINA, V.R. (2019)
. The tested compound is comparable, in terms of its activity to the hepatoprotective drug SAM according
A RANDOMIZED PHASE 2 STUDY OF LONG-ACTING TRANSCON GH VS DAILY GH IN CHILDHOOD GH DEFICIENCY
Chatelain, Pierre, Malievskiy, Oleg, Radziuk, Klaudziya, Senatorova, Ganna, Abdou, Magdy O., Vlachopapadopoulou, Elpis, Skorodok, Yulia, Peterkova, Valentina, Leff, Jonathan A., Beckert, Michael (2017)
unrelated to the study drug. Injection site tolerance was good. One TransCon GH subject developed a low
PADI4 GENE POLYMORPHISM AS A PREDICTOR OF RESPONSE TO METHOTREXATE IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS
Nazarova, L.S., Danilko, K.V., Malievsky, V.A., Viktorova, T.V. (2016)
Background: Methotrexate (MTX) is the most widely used disease-modifying anti-rheumatic drug
The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study
Lomakin, NV, Bakirov, BA, Protsenko, DN, Mazurov, VI, Musaev, GH, Moiseeva, OM, Pasechnik, ES, Popov, VV, Smolyarchuk, EA, Gordeev, IG, Gilyarov, MY, Fomina, DS, Seleznev, AI, Linkova, YN, Dokukina, EA, Eremeeva, AV, Pukhtinskaia, PS, Morozova, MA, Zinkina-Orikhan, AV, Lutckii, AA (2021)
of adverse drug reactions was comparable between the groups. Conclusion In patients with radiologically
Counseling about sudden unexpected death in epilepsy (SUDEP): A global survey of neurologists' opinions
Asadi-Pooya, AA, Trinka, E, Brigo, F, Hingray, C, Karakis, I, Lattanzi, S, Valente, KD, Contreras, G, Turuspekova, ST, Kishk, NA, Aljandeel, G, Farazdaghi, M, Lopez, YC, Kissani, N, Triki, C, Kramer, G, Surges, R, Mesraoua, B, Yu, HY, Daza-Restrepo, A, Alsaadi, T, Al-Asmi, A, Kutlubaev, MA, Pretorius, C, Jusupova, A, Khachatryan, SG, Ranganathan, LN, Ashkanani, A, Tomson, T, Gigineishvili, D (2022)
-clonic seizures, or with drug-resistant epilepsy. The propensity to tell all patients with epilepsy (PWE) about
BRENTUXIMAB VEDOTIN WITH CHEMOTHERAPY FOR STAGE III OR IV HODGKIN'S LYMPHOMA
CONNORS, J.M., SAVAGE, K.J, JURCZAK, W, LECH-MARANDA, E., SMOLEWSKI, P, WALEWSKI, J, STRAUS, D.J., YOUNES, A., ANSELL, S.M., KIM, W.S., GALLAMINI, A., ALEKSEEV, S., ILLÉS, A., ROSTA, A., PICARDI, M., ZINZANI, P.L., OKI, Y., FELDMAN, T., BARTLETT, N.L., CHEN, R., RAMCHANDREN, R., CUNNINGHAM, D., RADFORD, J., JOSEPHSON, N.C., SONG, E., SACHS, J., JOLIN, H.A., HUEBNER, D., LIU, R., LIPATOV, O.N. (2018)
BACKGROUND Brentuximab vedotin is an anti-CD30 antibody–drug conjugate that has been approved

Страница 6 из 8

Google Scholar
OpenDoar

Фасеты

Авторы
Ключевые слова
Год